AstraZeneca Global Media site
Australian media releases
All press releases
-
FIRST INHALED RESPIRATORY MEDICINE USING NEAR-ZERO GLOBAL WARMING POTENTIAL REGISTERED FOR USE IN AUSTRALIA
-
ONGOING ACCESS TO ZOLADEX® (goserelin) MONTHLY (3.6mg) IMPLANT IN AUSTRALIA
-
AUSTRALIANS LIVING WITH UNCONTROLLED SEVERE ASTHMA CAN NOW ACCESS A NEW TREATMENT ON THE PBS
-
MORE AUSTRALIANS LIVING WITH LUNG CANCER¹ CAN NOW ACCESS AN ORAL TARGETED TREATMENT ON THE PBS
-
AUSTRALIANS WITH CERTAIN BLOOD CANCERS CAN ACCESS AN ORAL COMBINATION THERAPY OPTION ON THE PBS
-
AUSTRALIANS LIVING WITH AN AGGRESSIVE AND LESS COMMON FORM OF LUNG CANCER CAN NOW ACCESS A NEW TREATMENT ON THE PBS
-
ELIGIBLE AUSTRALIANS WITH MUSCLE-INVASIVE BLADDER CANCER CAN ACCESS A NEW IMMUNOTHERAPY TREATMENT OPTION ON THE PBS
-
Intranasal Influenza Vaccine FluMist® (influenza virus vaccine) TGA Registered for use in Australian Children and Adolescents Aged 2 to 17 Years¹
-
ELIGIBLE AUSTRALIANS WITH ADVANCED LIVER CANCER CAN ACCESS FIRST DUAL IMMUNOTHERAPY TREATMENT OPTION ON THE PBS
-
ELIGIBLE AUSTRALIANS LIVING WITH METASTATIC BREAST CANCER CAN NOW ACCESS A TARGETED ORAL TREATMENT OPTION ON THE PBS
-
AUSTRALIANS WITH ADVANCED OR RECURRENT ENDOMETRIAL CANCER CAN ACCESS A NEW IMMUNOTHERAPY OPTION ON THE PBS
-
FIRST TARGETED TREATMENT ON THE PBS FOR RARE, UNPREDICTABLE AND DEBILITATING AUTOIMMUNE DISEASE, NMOSD
-
AUSTRALIANS WITH AN INHERITED FORM OF METASTATIC BREAST CANCER CAN NOW ACCESS A TARGETED TREATMENT OPTION ON THE PBS
-
FORXIGA® (dapagliflozin) AND XIGDUO® XR (dapagliflozin/metformin) NOW AVAILABLE FOR MORE PEOPLE WITH TYPE 2 DIABETES AND HIGH CARDIOVASCULAR RISK
-
AUSTRALIAN ADULTS WITH TYPE 2 DIABETES MELLITUS RECEIVE PBS ACCESS TO SIDAPVIA® 10/100 (dapagliflozin and sitagliptin)
-
ASTRAZENECA OPENS NEW RENEWABLE ENERGY PROJECT IN MACQUARIE PARK
-
ELIGIBLE AUSTRALIANS WITH A FORM OF METASTATIC BREAST CANCER CAN NOW ACCESS A TARGETED TREATMENT OPTION ON THE PBS
-
Australian children now have access to the first medication for inoperable plexiform neurofibromas
-
AUSTRALIANS WITH A HEREDITARY FORM OF HIGH-RISK, EARLY BREAST CANCER CAN NOW ACCESS A TARGETED, ORAL TREATMENT OPTION ON THE PBS
-
FIRST TARGETED TREATMENT FOR SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS LISTED ON THE PBS
-
NEW TARGETED TREATMENT ADDED TO THE PBS FOR EARLY-STAGE LUNG CANCER
-
ASTRAZENECA WELCOMES GOVERNMENT COMMITMENT TO CHEAPER MEDICINES, AND CALLS FOR FURTHER REFORM FOR EARLIER, FASTER AND FAIRER ACCESS
-
AUSTRALIANS WITH CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION RECEIVE PBS ACCESS TO FORXIGA® (DAPAGLIFLOZIN)
-
Ultomiris (ravulizumab rch) Receives PBS Reimbursement for Atypical Haemolytic Uraemic Syndrome (aHUS)
-
PBS access to targeted treatment will be expanded for more Australian women with ovarian cancer
-
Australian blood cancer patients to have PBS access to targeted therapy CALQUENCE® from 1 January 2024 as their first treatment option
-
Australians living with an agresseive and advanced form of lung cancer can now access a new treatment on the PBS
-
First new therapy in over a decade available on the PBS for Australians living with advanced biliary tract cancer - A rare and aggressive gastrointestinal cancer
-
Australians living with an aggressive form of metastatic breast cancer can now access a new treatment on the PBS
-
Blood cancer tablet CALQUENCE® to be listed on the PBS from 1 July 2023 for eligible Australian patients with relapsed/refractory mantle cell lymphoma, chronic lymphocytic leukaemia and small lymphocytic lymphoma
-
First New Treatment In More Than 20 Years Added To The PBS For People Living With Proteinuric Chronic Kidney Disease (CKD)
-
Ultomiris (ravulizumab-rmc) Now Available on the PBS to treat Paroxysmal Nocturnal Haemoglobinuria (PNH)
-
AstraZeneca’s Evusheld™ (Tixagevimab and Cilgavimab) Granted Provisional Approval For Pre-Exposure Prophylaxis (Prevention) Of COVID-19 In Australia’s Most At-Risk
-
Australians With One Of The Most Agressive Forms Of Blood Cancer Have New PBS Listed Treatment Option
-
AstraZeneca’s COVID-19 vaccine, Vaxzevria, hits two-billion dose supply milestone
-
AstraZeneca announces new treatment will be listed on the PBS from November 1st, 2021 to help manage COPD, Australia’s fifth leading cause of death
-
AstraZeneca’s COVID-19 vaccination guidance for employees
-
Australian production of AstraZeneca’s COVID-19 vaccine, Vaxzevria, to continue into 2022
-
Significant Advancement In Chronic Kidney Disease (CKD) Treatment With TGA Approval Of Forxiga (Dapagliflozin)
-
Name change to Vaxzevria from COVID-19 Vaccine AstraZeneca
-
Updated ATAGI advice on COVID-19 Vaccine AstraZeneca in response to Delta outbreaks
-
Recognition of locally-manufactured COVID-19 Vaccine AstraZeneca
-
AstraZeneca Australia & New Zealand response to the COVID-19 pandemic
-
AstraZeneca to plant 25 million trees in Australia and invest $200m in local manufacturing
-
AstraZeneca makes donation to support bushfire crisis across Australia